• Profile
Close

Patient reported outcomes following initiation of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in a specialist endocrinology practice of the LMC Diabetes Registry: The PROGRESS-Diabetes Study

Diabetes Research and Clinical Practice Aug 26, 2019

Brown RE, Abitbol A, Bajaj HS, et al. - In patients who started dulaglutide or liraglutide as part of usual clinical therapy, researchers conducted this observational study to compare patient-reported outcomes and clinical results. Between April 2017 and January 2018, adults with T2D who started dulaglutide or liraglutide were recruited. Using propensity score matching, clinical outcomes were evaluated in a post-hoc retrospective analysis. In real-world specialist practice, patients who started dulaglutide or liraglutide had comparable improvements in the satisfaction of diabetes medication and the satisfaction of the diabetes device. Important improvements in medication adherence scores were only seen in patients with dulaglutide. Comparable patterns of change in A1C were seen in both cohorts of treatment; liraglutide had significantly higher weight loss, like clinical trial findings.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay